About: Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 05 March 2011

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) наукова стаття, опублікована в березні 2011 (uk) artículu científicu espublizáu en marzu de 2011 (ast) scientific article published on 05 March 2011 (en) مقالة علمية نشرت في 05 مارس 2011 (ar)
publication date	wds:Q37850534-39ABA8D6-ABBA-4658-8EB8-3028E19B1307
publication date	2011-03-05 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37850534-D370AC3E-C64D-4CEC-88F6-1D6B5BAECD39
language of work or name	English
cites work	wds:Q37850534-0623B00B-722E-425E-803F-98261EF78615 wds:Q37850534-12EFBD30-922D-4D1C-AB9F-C4822722F0F9 wds:Q37850534-1F5F83D3-6074-4138-A10C-29A1322BADB8 wds:Q37850534-2493E064-DBFF-4C26-A602-1E030AE02F40 wds:Q37850534-2641221E-0F42-46C5-975C-BBC59D31CA7D wds:Q37850534-3C6AA0F3-5CE5-4BCC-9B75-F9155C407966 wds:Q37850534-3D0D2E79-223D-478B-97A9-892FF4AC4FF9 wds:Q37850534-48606E7A-52E5-4135-9A60-0AE25C17D35D wds:Q37850534-51BD94B3-6279-4AC4-9ACC-9F70CACCA346 wds:Q37850534-62114AF7-4C3F-4936-B851-07A05BFF59B6 wds:Q37850534-69082BBA-217D-46AB-92E6-64A5034F075D wds:Q37850534-7527B992-1518-420D-8DAF-57F89D97D10A wds:Q37850534-7BD17317-EC22-4057-921E-38CE9E7C029C wds:Q37850534-7DC314B6-2103-432C-B28C-0B1656E7B359 wds:Q37850534-7E94FD1D-9AA6-49F7-AAE1-3B0B04E721FE wds:Q37850534-94FA8AB1-2BAB-4A5B-98F0-65E93AF93FA6 wds:Q37850534-96082E70-85FA-4371-9C2F-7D1EA90DB8AF wds:Q37850534-99FD740A-FC13-4A84-8B60-736058A89001 wds:Q37850534-A0EFAA45-DD02-4D2E-A844-51CD0BE0F6EF wds:Q37850534-A6A22FFA-26E7-4157-997D-211E56180B94 wds:Q37850534-AF04E93F-4C2E-446A-A1F1-6F7218B399B3 wds:Q37850534-B7FF5709-7D14-4DF4-97B6-03610582FB46 wds:Q37850534-CB9AEBCB-4D99-482D-8A24-849F4A7FEC63 wds:Q37850534-CBFF7B4D-78A8-4DC2-A58C-6BE1DA6BD29A wds:Q37850534-DB2BFCF4-C5DA-4963-9985-6897A0975CF4
cites work	THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL Varicella mortality: trends before vaccine licensure in the United States, 1970-1994 Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Consensus: varicella vaccination of healthy children--a challenge for Europe Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine Outbreak of varicella at a day-care center despite vaccination. Varicella vaccine--are two doses better than one? Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting The burden of varicella in Germany. Potential risks and economic impact. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate va Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life A combination vaccine against measles, mumps, rubella and varicella. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Evaluation of a live attenuated mumps vaccine (Jeryl Lynn). With observations on the optimal time for testing serologic response A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella
author name string	wds:Q37850534-2AE6A67E-F0FC-4F94-BDA7-CA0DBAB1075C wds:Q37850534-33CD3F9A-05EA-4EF4-AE0A-65E2388C99EF wds:Q37850534-42CFC00C-7E18-451A-B0D8-062447592111 wds:Q37850534-5C30DCA7-671E-4106-9A71-14153ED3F052 wds:Q37850534-EA962F20-C91B-4C59-95F3-10F0F6744905 wds:Q37850534-FDBB3116-B872-4787-8D5D-5E237030D864 wds:Q37850534-FDBC968D-6CE4-48D9-AF21-537EC18010AE
author name string	P Willems A Malfroot H C Rümke K Helm K Hoppenbrouwers H P Loch M Douha
rdfs:label	Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (en) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (nl)
skos:prefLabel	Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (en) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (nl)
name	Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (en) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. (nl)
author	wds:Q37850534-0F697FAF-33F1-4CD7-8A3D-1B7DF596F068
author	Corinne Vandermeulen
title	wds:Q37850534-1191E2A0-0C6B-416A-B20B-70ECD40E7DB2
title	Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses (en)
page(s)	wds:Q37850534-3FB987B4-9CE0-44C8-8EC8-3D601BED4828
page(s)	3842-3849
instance of	wds:Q37850534-6dc3849b-acd7-411e-8062-e66a1d4a9e71 wds:Q37850534-7D964F84-391C-44BB-98D8-15C3EF6DD645
instance of	review article

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software